Navigation Links
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
Date:7/22/2008

BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed its strategic direction to develop its existing portfolio of compounds and the company will actively seek to acquire additional compounds and opportunities through Merger & Acquisition activity.

The strategic review was triggered by a recent accumulation of a number of factors that impacted the commercial return for the phase 3 PATHWAY trial.

The trial is unlikely to meet the forecast patient recruitment timetable and further significant delays were expected due to:

-- slower than expected regulatory processes in China, Korea and Vietnam;

-- slower than expected initiation of clinical sites;

-- slower than expected recruitment of patients into active sites; and

-- the recent launch of a competitive phase 3 trial, assessing Bayer/Onyx Nexavar(R) in the same indication.

Due to a lack of a global partner willing to meaningfully develop and commercialise PI-88, the commercial opportunity is much less than previously expected. Without a significant global partner contributing, Progen will be less able to expand into additional indications and exploit all potential PI-88 commercial opportunities.

These aspects would have delayed market entry significantly and seriously impacted on the commercial return of the phase 3 PATHWAY trial.

The next step is that Progen will seek expressions of interest in PI-88, at a regional level, initially from amongst those parties that had entered into Non-Disclosure Agreements and Due Diligence on PI-88.

The PI-88 trial had been facilitated through external agencies, and had resulted in 23 sites being opened for patient recruitment and 12 patients from 5 recruitment centres having be
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
3. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Progen Announces PI-88 Phase 2 Lung Cancer Results
9. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
(Date:5/22/2015)... , May 20, 2015 Research ... of the "Guide to Prepare Application Dossiers ... China (2014 Edition) " report to their ... is one of segment market of the most ... overseas medical device manufacturers and producers to penetrate ...
(Date:5/22/2015)... , May 22, 2015  In a sweeping analysis ... U.S., T1D Exchange researchers conclude that there ... 1 diabetes across all age groups, but especially for ... up-to-date picture of diabetes treatment, underscoring the need to ... technologies that can help type 1 patients achieve optimal ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... Seek-Find-Act-Follow: Innovations Span Entire Breast Care Continuum, from, Early Detection ... ... Care, CHICAGO, ... innovations to its,breast care portfolio, designed to help detect, diagnose and ...
... Alliance Pharmaceutical,Corp. (OTC Bulletin Board: ALLP). Following ... with its partner Beijing Double-Crane Pharmaceutical,Co., Ltd. ... for Oxygent(TM) (perfluorochemical [PFC] emulsion) to focus ... Oxygent in China. The,clinical development plan for ...
Cached Medicine Technology:Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio 2Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio 3Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio 4Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio 5Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan 2
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... Raleigh, NC (PRWEB) May 24, 2015 ... published a paper on air quality compliance issues that ... of American workers. Surviving Mesothelioma has just posted an ... it now. , The group found airborne asbestos ... inspection data collected between 1984 and 2011. , “Asbestos ...
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin markers ... to pin point locations on a map, to indicate prices or ... users to choose from 30 simplistic presets with geometric design elements ... editors can easily manipulate ProPin presets as a whole. Pixel ... , Using ProPin is easy, simply drag a preset into the ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... in west central Africa between 1884 and 1924 at root, ... most pervasive global strain of HIV began spreading in humans ... , The research, which is published in the current issue ... 1884 and 1924, around the same time urban centers in ...
... Women will recruit one million women to partner with ... to prevention, Celebrities already signed on as Army ... The Dr. Susan Love Research Foundation,and the Avon Foundation ... that will partner women with breast cancer,researchers to find ...
... Ticker Symbol: CUR, QUEBEC CITY, Oct. 1 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... CEO of the Company, will be presenting a ... Focus Conference on,Monday, October 6, 2008, at 1:30 ...
... Provides Comprehensive Solution to Complex Nursing ... ... Samarion Inc., the Long Term,Care (LTC) industry,s technology partner, ... home facilities reduce falls, reduce incidents of wandering,and elopement, eliminate ...
... Oct. 1 October 1, 2008 is a landmark,day ... the Tennessee,Long-Term Care Partnership that rewards Tennesseans for buying ... purchase of long-term,care insurance, Medicaid becomes the payer of ... more choices as a private-pay patient, and,the state Medicaid ...
... us that exploring the unknown can lead to important discoveries. Take health ... until 2004. Today, however, millions of people have explored this relatively new ... , ... MILWAUKEE (Business Wire EON) October 1, 2008 -- ...
Cached Medicine News:Health News:HIV Outbreak Began Decades Earlier Than Thought 2Health News:Love/Avon Army of Women Breast Cancer Research Initiative to Launch Today 2Health News:Love/Avon Army of Women Breast Cancer Research Initiative to Launch Today 3Health News:Love/Avon Army of Women Breast Cancer Research Initiative to Launch Today 4Health News:Love/Avon Army of Women Breast Cancer Research Initiative to Launch Today 5Health News:DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008 2Health News:Samarion(SM) to Have Major Presence at the AHCA/NACL/MECF 59th Annual Convention & Expo 2Health News:Tennessee Introduces Long-Term Care Partnership Insurance Policies and Producer Training Requirement 2Health News: Discover a World of Savings with Health Savings Accounts (HSAs) 2
Ovarian Cancer Test...
Test for prostatic acid phosphatase...
... If you could imagine the ultimate ... it maximize efficiency? Would its control systems ... flexible enough to quickly adapt to different ... you no longer need to imagine this ...
... world's first Windows 2000 notebook PC ... allows data sharing with other Windows ... Microsoft Office 2000. Data and waveforms ... large, sharp 14.1-inch TFT screen with ...
Medicine Products: